The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration-Reference-Cited by-同舟云学术

The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration

Published:2013-11-26 Issue:8 Volume:54 Page:850-857
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Kim Ho-Sook¹²,Cho Doo-Yeoun¹²,Park Bo-Min¹²,Bae Soo-Kyoung²,Yoon Yune-Jung²,Oh Minkyung¹,Ghim Jong-lyul¹²,Kim Eun-Young¹²,Kim Dong-Hyun¹,Shin Jae-Gook¹²

Affiliation:

1. Department of Pharmacology and PharmacoGenomics Research Center; Inje University College of Medicine; Busan Republic of Korea

2. Department of Clinical Pharmacology; Inje University Busan Paik Hospital; Busan Republic of Korea

Funder

Ministry for Health & Welfare, Korea

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.225/fullpdf

Reference27 articles.

1. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators;Leon;N Engl J Med.,1998

2. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite;Kazui;Drug Metab Dispos.,2010

3. Paraoxonase-1 is a major determinant of clopidogrel efficacy;Bouman;Nat Med.,2011

4. Paraoxonase-1 and clopidogrel efficacy;Dansette;Nat Med.,2011

5. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study;Fontana;J Thromb Haemost.,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Advanced Technologies—Nanotechnology, Genomics Technology, and 3D Printing Technology—In Precision Anesthesia: A Comprehensive Narrative Review;Pharmaceutics;2023-09-06

2. The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-02

3. Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes;Frontiers in Pharmacology;2020-12-17

4. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects;Clinical Therapeutics;2018-07

5. Impact of CYP2C19 Polymorphism on Antiplatelet Potency of Prasugrel 5 and 10 mg Daily Maintenance;Cardiology;2018